Premium
Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon®) on rat prostate hyperplasia induced by hyperprolactinemia: Comparison with finasteride
Author(s) -
Van Coppenolle Fabien,
Le Bourhis Xuefen,
Carpentier Françoise,
Delaby Geoffrey,
Cousse Henri,
Raynaud JeanPierre,
Dupouy JeanPaul,
Prevarskaya Natalia
Publication year - 2000
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(20000401)43:1<49::aid-pros7>3.0.co;2-j
Subject(s) - finasteride , hyperplasia , prostate , prolactin , dihydrotestosterone , endocrinology , testosterone (patch) , medicine , sulpiride , antiandrogens , androgen , hormone , antiandrogen , antagonist , receptor , cancer
BACKGROUND The growth of the prostate gland is mainly dependent on androgens. Other hormones, like prolactin (PRL), also influence prostate development. Our purpose was to analyze and compare the effects of two drugs (5α‐reductase inhibitor) used in the therapy of benign prostatic hyperplasia: lipidosterolic extract of Serenoa repens (LSESR), and finasteride in an in vivo model of rat prostate hyperplasia induced by hyperprolactinemia. METHODS Hyperprolactinemia was induced by 30 daily injections of sulpiride. Wistar rats received daily gavages of LSESR or finasteride. We used the following groups: control, castrated, castrated with a substitute testosterone (T), or 5α‐dihydrotestosterone (DHT) implant. RESULTS Hyperprolactinemia increases the wet weight and induces hyperplasia in the lateral prostate (LP). Unlike finasteride, LSESR significantly reduced LP growth and hyperplasia in castrated, DHT‐implanted, and sulpiride‐treated rats. CONCLUSIONS Finasteride was only capable of inhibiting the effect of androgens on rat prostate enlargement. LSESR inhibited not only the androgenic but also the trophic effect of PRL in rat LP hyperplasia. Prostate 43:49–58, 2000. © 2000 Wiley‐Liss, Inc.